High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis

Digestive and Liver Disease

Volumn 41, Issue 8, 2009, Pages 555-558

  Severi, C ^a   Abdullahi, M ^a   Tari, R ^a   Vannella, L ^a   Marcheggiano, A ^a   Capoccia, D ^a   Leonetti, F ^a   Osborn, J ^a   Annibale, B ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bismuth; H. pylori eradication; Pangastritis; Proton pump inhibitors

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CARBON 14; LANSOPRAZOLE; METRONIDAZOLE; UREA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GASTRITIS; HEADACHE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT OUTCOME; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 67649641678     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.11.009     Document Type: Article

References (29)

1. Lee J.M., Breslin N.P., Hyde D.K., Buckley M.J., and O'Morain C.A. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 13 (1999) 489-496
2. Mègraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53 (2004) 1374-1384
3. Fuccio L., Minardi M.E., Zagari R.M., Grilli D., Magrini N., and Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Intern Med 147 (2007) 553-562
4. Laine L., Fennerty M.B., Osato M., Sugg J., Suchower L., Probst P., et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 95 (2000) 3393-3398
5. Gerrits M.M., van Vliet A.H., Kuipers E.J., and Kusters J.G. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis 6 (2006) 699-709
6. Dixon M.F. The components of gastritis. Histology and pathogenesis. In: Graham D.Y., Genta R.M., and Dixon M.F. (Eds). Gastritis (1999), Lippincott Williams & Wilkings, Philadelphia 51-66
7. El-Omar E.M., Oien K., El-Nujumi A., Gillen D., Wirz A., Dahill S., et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113 (1997) 15-24
8. Derakhshan M.H., El-Omar E., Oien K., Gillen D., Fyfe V., Crabtree J.E., et al. Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. J Clin Pathol 59 (2006) 1293-1299
9. Furuta T., Baba S., Takashima M., Futami H., Arai H., Kajimura M., et al. Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterol 33 (1998) 357-363
10. Sipponen P., Kekki M., Seppala K., and Siurala M. The relationship between chronic gastritis and gastric acid secretion. Aliment Pharmacol Ther 10 (1996) 103-118
11. Vakil N. Helicobacter pylori: factors affecting eradication and recurrence. Am J Gastroenterol 100 (2005) 2392-2394
12. Lambert J.R., and Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther Suppl. 1 (1997) 27-33
13. Dore M.P., Graham D.Y., Mele R., Marras L., Nieddu S., Manca A., et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 97 (2002) 857-860
14. Capurso G., Martino G., Grossi C., Annibale B., and Delle Fave G. Hypersecretory duodenal ulcer and Helicobacter pylori infection: a four-year follow-up study. Dig Liver Dis 32 (2000) 119-124
15. Dixon M.F., Genta R.M., Yardley J.H., and Correa P. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 20 (1996) 1161-1181
16. Annibale B., D'Ambra G., Luzzi I., Marcheggiano A., Iannoni C., Paoletti M., et al. Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients?. Am J Gastroenterol 92 (1997) 790-794
17. Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J, et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008;18:1450-4.
18. Blaser M.J., and Atherton J.C. Helicobacter pylori persistence: biology and disease. J Clin Invest 113 (2004) 321-333
19. Broutet N., Tchamgouè S., Pereira E., Lamouliatte H., Salomon R., and Mègraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 17 (2003) 99-109
20. Annibale B., Marignani M., Monarca B., Antonelli G., Marcheggiano A., Martino G., et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 131 (1999) 668-672
21. Gisbert J.P., Pajares R., and Pajares J.M. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 12 Suppl. 2 (2007) 50-58
22. Goddard A.F. Review article: factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther 12 (1998) 1175-1184
23. Veldhuyzen van Zanten S.J., and Sherman P.M. Indications for treatment of Helicobacter pylori infection: a systematic overview. CMAJ 150 (1994) 189-198
24. Veldhuyzen Van Zanten S., Farley A., Marcon N., Lahaie R., Archambault A., Hunt R., et al. Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study. Can J Gastroenterol 14 (2000) 599-602
25. Malfertheiner P., Megraud F., O'Morain C., Bazzoli F., El-Omar E., Graham D., et al. Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report. Gut 56 (2007) 772-781
26. Veldhuyzen Van Zanten S., and Chiba N. What is the role of bismuth in Helicobacter pylori antimicrobial resistance?. In: Hunt R.H., and Tytgat G.N.J. (Eds). Helicobacter pylori. Basic mechanisms to clinical cure 2000 (2000), Kluwer Academic Publishers, Dordrecht 593-599
27. Ge R., Sun X., Gu Q., Watt R.M., Tanner J.A., Wong B.C.Y., et al. A proteomic approach for the identification of bismuth-binding proteins in Helicobacter pylori. J Biol Inorg Chem 12 (2007) 831-842
28. Tanaka S., Guth P.H., Carryl O.R., and Kaunitz J.D. Cytoprotective effect of bismuth subsalicylate in indomethacin-treated rats is associated with enhanced mucus bismuth concentration. Aliment Pharmacol Ther 11 (1997) 605-612
29. Capurso G., Lahner E., Marcheggiano A., Caruana P., Carnuccio A., Bordi C., et al. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with Helicobacter pylori infection. Aliment Pharmacol Ther 15 (2001) 1753-1761